In a first-of-its-kind move by a drug maker, Teva Pharmaceuticals (TEVA) recently sold $5 billion in bonds that are tied directly to its progress in achieving goals linked to climate change and making medicines accessible in certain low and middle-income countries.
The goal is to increase the cumulative number of marketing applications submitted to regulators in low and middle-income countries — as well as the volume of donated medicines — by 150% by 2025, compared with the four-year period starting in 2017. The treatments must be considered essential medicines by the World Health Organization and would be used for diabetes and heart disease, among other ailments.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
